EP1353937A4 - SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY - Google Patents
SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPYInfo
- Publication number
- EP1353937A4 EP1353937A4 EP01994329A EP01994329A EP1353937A4 EP 1353937 A4 EP1353937 A4 EP 1353937A4 EP 01994329 A EP01994329 A EP 01994329A EP 01994329 A EP01994329 A EP 01994329A EP 1353937 A4 EP1353937 A4 EP 1353937A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- human antibodies
- cancer therapy
- specific human
- selective cancer
- selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US751181 | 1996-11-15 | ||
US75118100A | 2000-12-29 | 2000-12-29 | |
PCT/US2001/049440 WO2002059264A2 (en) | 2000-12-29 | 2001-12-31 | Specific human antibodies for selective cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1353937A2 EP1353937A2 (en) | 2003-10-22 |
EP1353937A4 true EP1353937A4 (en) | 2005-04-13 |
Family
ID=25020844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01994329A Withdrawn EP1353937A4 (en) | 2000-12-29 | 2001-12-31 | SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1353937A4 (zh) |
JP (1) | JP2004524023A (zh) |
KR (1) | KR20030091952A (zh) |
CN (1) | CN100374456C (zh) |
AU (1) | AU2002246737B2 (zh) |
BR (1) | BR0116763A (zh) |
CA (1) | CA2433227A1 (zh) |
CZ (1) | CZ20031983A3 (zh) |
HU (1) | HUP0400775A2 (zh) |
IL (1) | IL156690A0 (zh) |
MX (1) | MXPA03005944A (zh) |
NZ (1) | NZ527173A (zh) |
PL (1) | PL365758A1 (zh) |
RU (1) | RU2316564C2 (zh) |
WO (1) | WO2002059264A2 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2491427A1 (en) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
CA2531283A1 (en) * | 2003-06-30 | 2005-01-20 | Bio-Technology General (Israel) Ltd. | Specific human antibodies |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
WO2010078916A1 (en) * | 2008-12-19 | 2010-07-15 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
US9211344B2 (en) * | 2010-07-09 | 2015-12-15 | Affibody Ab | Polypeptides |
CN101948534B (zh) * | 2010-08-19 | 2014-05-28 | 中国科学院生物物理研究所 | 一种筛选抗体的方法 |
GB201310544D0 (en) * | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
ES2731876T3 (es) * | 2014-10-23 | 2019-11-19 | Singh Molecular Medicine Llc | Anticuerpos de dominio sencillo contra antígenos intracelulares |
CA2970255A1 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
CN114195882A (zh) * | 2015-10-01 | 2022-03-18 | 圣拉斐尔医院有限公司 | Tcr及其用途 |
AU2016358296B2 (en) * | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
DK4050034T3 (da) * | 2016-09-14 | 2024-06-03 | Teneoone Inc | Cd3-bindende antistoffer |
WO2022103961A1 (en) * | 2020-11-13 | 2022-05-19 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9806793A (pt) * | 1997-01-22 | 2000-05-16 | Univ Texas | Processos e composições de fator tissular para coagulação e tratamento de tumores. |
-
2001
- 2001-12-31 CZ CZ20031983A patent/CZ20031983A3/cs unknown
- 2001-12-31 AU AU2002246737A patent/AU2002246737B2/en not_active Ceased
- 2001-12-31 CN CNB018228852A patent/CN100374456C/zh not_active Expired - Fee Related
- 2001-12-31 JP JP2002559551A patent/JP2004524023A/ja active Pending
- 2001-12-31 HU HU0400775A patent/HUP0400775A2/hu unknown
- 2001-12-31 CA CA002433227A patent/CA2433227A1/en not_active Abandoned
- 2001-12-31 PL PL01365758A patent/PL365758A1/xx unknown
- 2001-12-31 MX MXPA03005944A patent/MXPA03005944A/es not_active Application Discontinuation
- 2001-12-31 BR BR0116763-4A patent/BR0116763A/pt not_active IP Right Cessation
- 2001-12-31 IL IL15669001A patent/IL156690A0/xx unknown
- 2001-12-31 EP EP01994329A patent/EP1353937A4/en not_active Withdrawn
- 2001-12-31 RU RU2003123100/13A patent/RU2316564C2/ru not_active IP Right Cessation
- 2001-12-31 WO PCT/US2001/049440 patent/WO2002059264A2/en active IP Right Grant
- 2001-12-31 NZ NZ527173A patent/NZ527173A/xx unknown
- 2001-12-31 KR KR10-2003-7008885A patent/KR20030091952A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
Non-Patent Citations (7)
Title |
---|
ADAMS G P ET AL: "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu", BRITISH JOURNAL OF CANCER, vol. 77, no. 9, May 1998 (1998-05-01), pages 1405 - 1412, XP009037431, ISSN: 0007-0920 * |
DE KRUIF J ET AL: "New perspectives on recombinant human antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 17, no. 10, 1 October 1996 (1996-10-01), pages 453 - 455, XP004034704, ISSN: 0167-5699 * |
DE KRUIF J ET AL: "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 9, 25 April 1995 (1995-04-25), pages 3938 - 3942, XP002149535, ISSN: 0027-8424 * |
HOOGENBOOM H R ET AL: "Antibody phage display technology and its applications", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 1 - 20, XP004127382, ISSN: 1380-2933 * |
HOOGENBOOM H R: "Designing and optimizing library selection strategies for generating high-affinity antibodies", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 62 - 70, XP004034115, ISSN: 0167-7799 * |
HUDSON P J ET AL: "High avidity scFv multimers; diabodies and triabodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 177 - 189, XP004186084, ISSN: 0022-1759 * |
NISSIM A ET AL: "ANTIBODY FRAGMENTS FROM A 'SINGLE POT' PHAGE DISPLAY LIBRARY AS IMMUNOCHEMICAL REAGENTS", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 3, 1994, pages 692 - 698, XP002926488, ISSN: 0261-4189 * |
Also Published As
Publication number | Publication date |
---|---|
CZ20031983A3 (cs) | 2005-07-13 |
NZ527173A (en) | 2006-03-31 |
HUP0400775A2 (en) | 2007-05-02 |
KR20030091952A (ko) | 2003-12-03 |
JP2004524023A (ja) | 2004-08-12 |
AU2002246737B2 (en) | 2007-03-01 |
CN100374456C (zh) | 2008-03-12 |
WO2002059264A2 (en) | 2002-08-01 |
WO2002059264A3 (en) | 2003-03-06 |
IL156690A0 (en) | 2004-01-04 |
EP1353937A2 (en) | 2003-10-22 |
MXPA03005944A (es) | 2005-04-29 |
CN1551886A (zh) | 2004-12-01 |
BR0116763A (pt) | 2004-03-09 |
PL365758A1 (en) | 2005-01-10 |
RU2003123100A (ru) | 2005-03-10 |
RU2316564C2 (ru) | 2008-02-10 |
CA2433227A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1311262A4 (en) | COMBINED TREATMENT AGAINST CANCER | |
GB2386120B (en) | Differentiated cells suitable for human therapy | |
EP1572131A4 (en) | ANTIBODY THERAPY | |
GB0028429D0 (en) | Therapy | |
EP1296698A4 (en) | THERAPEUTIC COMPOUNDS | |
IL214262A0 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
AU2001251348A1 (en) | Apparatus for sensing human prostate tumor | |
IL156690A0 (en) | Specific human antibodies for selective cancer therapy | |
HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
GB2367993B (en) | Radiotherapy apparatus | |
EP1178829A4 (en) | HUMAN MONOCLONAL ANTIBODY | |
AU2002351374A8 (en) | Antibodies to treat cancer | |
GB0001710D0 (en) | Therapeutic treatment | |
GB0005257D0 (en) | Breast cancer hormonal therapy | |
EP1401494A4 (en) | TUMOR THERAPY | |
AU144325S (en) | Therapy device | |
AU2096002A (en) | Therapeutic treatment | |
GB0026015D0 (en) | Cancer treatment | |
GB2374018B (en) | Ultrasound therapy | |
GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy | |
EP1463511A4 (en) | COMBINATORY ANTICANCER THERAPY | |
SI1157041T1 (sl) | Protitelesa za terapijo in diagnozo raka | |
GB0024673D0 (en) | Therapeutic antibodies | |
GB9914057D0 (en) | Antibody therapy | |
GB9927698D0 (en) | Therapeutic antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030728 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060133 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SAVIENT PHARMACEUTICALS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050225 |
|
17Q | First examination report despatched |
Effective date: 20080121 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080603 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1060133 Country of ref document: HK |